Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1845-1849

  Han, Ke ^a   Shao, Xiaoping ^a   Zheng, Huizhen ^a   Wu, Chenggang ^a   Zhu, Jianqiong ^b   Zheng, Xiaoli ^c   Zhang, Yonghui ^a  

^a GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Dongguan Center for Disease Control and Prevention   (China)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hepatitis B vaccine; Influence factors; Low responder; Non responder; Revaccination

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HEPATITIS VACCINE;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; DRUG EFFICACY; DRUG FEVER; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; LOW BIRTH WEIGHT; MALE; REVACCINATION; RISK FACTOR; SEROCONVERSION; TREATMENT RESPONSE;

HEPATITIS B VACCINE; INFLUENCE FACTORS; LOW-RESPONDER; NON-RESPONDER; REVACCINATION;

CHINA; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; MALE; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84872248508     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21818     Document Type: Article

References (45)

1. Wang LD. Vaccination practice and management. Beijing: People's medical publishing house 2006:187.
2. The report of seroepidemiological survey on hepatitis B in Chinese people. Ministry of health of the people's republic of China, Centers for disease control and prevention of China. Beijing: People's medical publishing house 2011: 79.
3. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999; 18:57-67; PMID:10501235; http://dx.doi.org/ 10.1016/S0264-410X(99)00179-6.
4. World Health Organization. Expanded Program on Immunization, Global Advisory Group. Wkly Epidemiol Rec 1992; 3:11-6.
5. Sun ZT, Ming LH, Zhu X, Lu JH. Prevention and control of hepatitis B in China. J Med Virol 2002; 67:447-50; PMID:12116043; http://dx.doi.org/10.1002/ jmv.10094.
6. Goudeau A, Coursaget P, Barin F, et al. Prevention of hepatitis B by active and passive active immunization. Viral Hepatitis 1982: 509-525.
7. Redeker AG, Mosley JW, Gocke DJ, McKee AP, Pollack W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med 1975; 293:1055-9; PMID:1101065; http://dx.doi.org/10. 1056/NEJM197511202932101.
8. Seeff LB, Wright EC, Zimmerman HJ, Alter HJ, Dietz AA, Felsher BF, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978; 88:285-93; PMID:343678.
9. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14; PMID:2941687; http://dx.doi.org/10.1056/NEJM198607243150401.
10. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179:489-92; PMID:9878036; http://dx.doi.org/10.1086/314578.
11. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325:569-73; PMID:12228132; http://dx.doi.org/10.1136/bmj.325.7364.569.
12. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 1991; 337:747-50; PMID:1672389; http://dx.doi.org/10.1016/0140-6736(91) 91367-4.
13. Hofmann F, Kralj N. Criteria for successful hepatitis B vaccination in adults: results of a case study. Infection 2009; 37:266-9; PMID:18854934; http://dx.doi.org/10.1007/s15010-008-7410-y.
14. STIKO. Empfehlung der standikegen impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002 Epid Bull 2002; 28:227-42.
15. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984; 52:396-402; PMID:6492255.
16. Tedder RS, Zuckerman M, Brink N. Hepatitis B vaccination. Non-responders must be detected .... BMJ 1993; 307:732; PMID:8401100; http://dx.doi.org/10. 1136/bmj.307.6906.732.
17. An S, Jia H, Han Y, et al. Meta-analysis of the immunogenicity of different dosages of yeast recombinant hepatitis B vaccine. Chinese journal of health statistics 2009; 26:398-399.
18. Chen B, Liu L, Zhang JY, et al. Meta-analysis of the immunogenicity of 5 μg and 10 μg dosages of a recombinant hepatitis B vaccine. Mod Prev Med 2010; 37:611-4.
19. Belloni C, Tinelli C, Orsolini P, et al. Revaccination against hepatitis B virus of non-responding and low responding infants immunized at birth. A parallel evaluation of rubella and tetanus vaccine. Vaccine 1998; 6:399-402; http://dx.doi.org/10.1016/S0264-410X(97)80917-6.
20. Cook IF, Murtagh J. Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants. J Paediatr Child Health 2002; 38:393-6; PMID:12174003; http://dx.doi.org/10.1046/ j.1440-1754.2002.00013.x.
21. Junqueira AL, Tavares VR, Martins RM, Frauzino KV, da Costa e Silva AM, Minamisava R, et al. Safety and immunogenicity of hepatitis B vaccine administered into ventrogluteal vs. anterolateral thigh sites in infants: a randomised controlled trial. Int J Nurs Stud 2010; 47:1074-9; PMID:20189173; http://dx.doi.org/10.1016/j.ijnurstu.2010.01.009.
22. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87(3A):36S-40S; PMID:2528297; http://dx.doi.org/10.1016/0002-9343(89) 90530-5.
23. Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, Tachibana Yoshida CF, Sandoval de Souza CB. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine 2002; 20:1557-62; PMID:11858862; http://dx.doi.org/10.1016/S0264-410X(01)00493-5.
24. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine 2007; 25:3511-4; PMID:17400337; http://dx.doi.org/10.1016/j.vaccine.2005.09.037.
25. Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103:E14; PMID:9925860; http://dx.doi.org/10.1542/peds.103.2.e14.
26. Ghebrehewet S, Baxter D, Falconer M, Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum Vaccin 2008; 4:280-5; PMID:18398298; http://dx.doi.org/10.4161/hv.4.4.5687.
27. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin Liver Dis 2004; 8:283-300; PMID:15481341; http://dx.doi.org/10.1016/j.cld.2004.02.010.
28. Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003; 23:309-14; PMID:14708890; http://dx.doi.org/10.1034/j.1478-3231.2003.00865.x.
29. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999; 17:2946-50; PMID:10462228; http://dx.doi.org/10. 1016/S0264-410X(99)00178-4.
30. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993; 17:475-9; PMID:8218692; http://dx.doi.org/10.1093/clinids/17.3.475.
31. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985; 254:3187-9; PMID:2933532; http://dx.doi.org/10.1001/jama.1985.03360220053027.
32. Shaw FE Jr., Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-30; PMID:2530717; http://dx.doi.org/10.1016/0264-410X(89)90157-6.
33. Malekzadeh R, Khatibian M, Rezvani M. Viral hepatitis in the world and Iran. J Iran Med Council 1997; 15:183-200.
34. Szmmuness W, Stevens CE, Harlay EJ, et al. Hepatitis B vaccine: demonstration of efficacy in the United States. N Engl J Med 1980:303.
35. Chirico G, Belloni C, Gasparoni A, Cerbo RM, Rondini G, Klersy C, et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 1993; 92:717-9; PMID:8414862.
36. Belloni C, Chirico G, Pistorio A, Orsolini P, Tinelli C, Rondini G. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998; 87:336-8; PMID:9560044; http://dx.doi.org/10.1111/j.1651-2227.1998. tb01448.x.
37. Faldella G, Alessandroni R, Magini GM, Perrone A, Sabatini MR, Vancini A, et al. The preterm infant's antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine. Vaccine 1998; 16:1646-9; PMID:9713941; http://dx.doi.org/10.1016/S0264-410X(98)00060-7.
38. Huang FY, Lee PI, Lee CY, Huang LM, Chang LY, Liu SC. Hepatitis B vaccination in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77:F135-8; PMID:9377137; http://dx.doi.org/10.1136/fn.77.2.F135.
39. Belson A, Reif S, Peled Y, Bujanover Y. Immune response to hepatitis B virus vaccine in 1-year-old preterm and term infants. J Pediatr Gastroenterol Nutr 1996; 23:252-5; PMID:8890074; http://dx.doi.org/10.1097/00005176-199610000- 00008.
40. Amani A, Shoekri F. Immunogenicity of a recombinant hepatitis B vaccine inI ranian neonates: high frequeney of unresponsiveness in dependent of the carrier state of mothers. Iran J Med Sci 1995; 20:87-92. (Pubitemid 26189293)
41. Tian C, Li J, Han CZ, et al. Immunization effectiveness and influence factors of hepatitis B vaccination of newborns in China. Chin J Publ Health 2007; 23:678-9.
42. Deng XQ, Xu ZY, Ouyang PY, et al. Relationship between titre of maternal serum hepatitis B surface antigen, e antigen and failure of neonatal hepatitis B immunization. Chinese. J Infect Dis 2000; 18:232-5.
43. American Academy of Pediatrics Committee on Infectious Diseases. Universal hepatitis B immunization. Pediatrics 1992; 89:795-800; PMID:1557285.
44. Orsolini P, Belloni C, Klersy C, Campisi D, Chirico G, Togni C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine 1995; 13:551-4; PMID:7483775; http://dx.doi.org/10.1016/0264-410X(94)00043-M.
45. Windebank KP, Faux JA, Chapel HM. ELISA determination of IgG antibodies to pneumococcal capsular polysaccharides in a group of children. J Immunol Methods 1987; 104:143-8; PMID:3680953; http://dx.doi.org/10.1016/0022-1759(87) 90498-4.